• Earlier in 2026, Boston Scientific reported solid Q1 results with 11.6% year-over-year revenue growth, but its initial 2026 guidance came in below market expectations and highlighted slowing momentum in its electrophysiology business.
• The electrophysiology slowdown, where Medtronic appears to be gaining share, raises questions about Boston Scientific’s competitive positioning in a segment that has been an important growth contributor.
• We’ll now examine how softer guidance and electrophysiology competition may influence Boston Scientific’s previously bullish investment narrative and growth assumptions.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 14 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Boston Scientific Investment Narrative Recap

To own Boston Scientific, you need to believe its broad cardiovascular and MedSurg portfolio can offset pockets of weakness like electrophysiology. The latest Q1 results showed strong overall growth, but softer 2026 guidance and EP share pressure from Medtronic may temper near term enthusiasm and make EP execution the key short term catalyst and risk to watch. If EP growth remains under pressure, it could challenge prior assumptions about Boston Scientific’s strongest engine.

In that context, the company’s April 22 guidance update, cutting full year 2026 reported net sales growth expectations to about 7.0% to 8.5% from the earlier 10.5% to 11.5%, looks especially relevant. It ties the electrophysiology slowdown directly into lower growth expectations, reinforcing that the company’s biggest near term question is not its diversified platform, but whether it can stabilize EP growth while continuing to invest in higher potential areas like WATCHMAN and pulsed field ablation.

Yet before you dismiss the story, you should be aware of how EP pressure could interact with…

Boston Scientific’s narrative projects $25.9 billion revenue and $4.8 billion earnings by 2029.

Uncover how Boston Scientific's forecasts yield a $77.10 fair value, a 70% upside to its current price.

Exploring Other Perspectives

Before this EP slowdown, the most optimistic analysts were assuming revenue could reach about US$28.0 billion and earnings US$6.0 billion by 2029, which is far more bullish than the baseline narrative and leans heavily on sustained electrophysiology strength; this news suggests those upbeat scenarios may need revisiting, so you should compare these competing viewpoints and decide which assumptions you find more realistic.

Explore 7 other fair value estimates on Boston Scientific - why the stock might be worth just $76.48!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Boston Scientific research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Boston Scientific research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Boston Scientific's overall financial health at a glance.

Ready For A Different Approach?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Capitalize on the AI infrastructure supercycle with our selection of the 49 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.